Burden of chickenpox complications in Poland, 2006 to 2021: A comprehensive registry-based study
ConclusionsOur findings suggest that the implementation of a universal chickenpox immunisation programme, supported by health education, should be considered to reduce the number of hospitalisations and nearly eliminate deaths because of chickenpox. (Source: Eurosurveillance)
Source: Eurosurveillance - February 29, 2024 Category: Infectious Diseases Authors: Rafa ł Halik, Iwona Paradowska-Stankiewicz, Aneta Trochonowicz and Swavik Dittmer Source Type: research
Effectiveness of interventions to increase healthcare workers ’ adherence to vaccination against vaccine-preventable diseases: a systematic review and meta-analysis, 1993 to 2022
ConclusionInterventions aimed at increasing HCWs’ adherence to vaccination against VPDs are effective, especially multi-component ones. Future research should determine the most effective framework of interventions for each setting, using appropriate study design for their evaluation, and should compare intervention components to understand their contribution to the effectiveness. (Source: Eurosurveillance)
Source: Eurosurveillance - February 29, 2024 Category: Infectious Diseases Authors: Marco Clari, Beatrice Albanesi, Rosanna Irene Comoretto, Alessio Conti, Erika Renzi, Michela Luciani, Davide Ausili, Azzurra Massimi and Valerio Dimonte Source Type: research
Epidemiology of gonorrhoea: systematic review, meta-analyses, and meta-regressions, World Health Organization European Region, 1949 to 2021
ConclusionsNeisseria gonorrhoeae epidemiology in Europe has distinct and contrasting epidemiologies for vaginal sex transmission in heterosexual sex networks vs anal and oral sex transmission in MSM sexual networks. Increased transmission may facilitate drug-resistant strain emergence. Europe is far from achieving the World Health Organization target of 90% incidence reduction by 2030. (Source: Eurosurveillance)
Source: Eurosurveillance - February 29, 2024 Category: Infectious Diseases Authors: Omar Chidiac, Sawsan AlMukdad, Manale Harfouche, Emma Harding-Esch and Laith J Abu-Raddad Source Type: research
Authors ’ correction for Euro Surveill. 2024;29(3)
(Source: Eurosurveillance)
Source: Eurosurveillance - February 22, 2024 Category: Infectious Diseases Authors: Eurosurveillance editorial team Source Type: research
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: ͨ...
Source: Eurosurveillance - February 22, 2024 Category: Infectious Diseases Authors: Marine Maurel, Jennifer Howard, Esther Kissling, Francisco Pozo, Gloria P érez-Gimeno, Silke Buda, Noémie Sève, Adele McKenna, Adam Meijer, Ana Paula Rodrigues, Iván Martínez-Baz, Ivan Mlinarić, Neus Latorre-Margalef, Gergő Túri, Mihaela Lazăr, C Source Type: research
Clinical isolates of ST131 blaOXA-244-positive Escherichia coli, Italy, December 2022 to July 2023
We report clinical isolates of OXA-244-producing ST131E. coli in four patients admitted to an acute care hospital in Pavia, Italy. The association of this difficult-to-detect determinant with a globally circulating high-risk clone, ST131E. coli, is of clinical relevance. (Source: Eurosurveillance)
Source: Eurosurveillance - February 22, 2024 Category: Infectious Diseases Authors: Aurora Piazza, Marta Corbella, Vittoria Mattioni Marchetti, Cristina Merla, Irene Mileto, Angela Kuka, Greta Petazzoni, Stefano Gaiarsa, Roberta Migliavacca, Fausto Baldanti and Patrizia Cambieri Source Type: research
Wastewater-based reproduction numbers and projections of COVID-19 cases in three areas in Japan, November 2021 to December 2022
ConclusionOur study demonstrates how wastewater data can be used to track reproduction numbers and perform scenario modelling to inform policy decisions. The proposed framework complements conventional clinical surveillance, especially when reliable and timely epidemiological data are not available. (Source: Eurosurveillance)
Source: Eurosurveillance - February 22, 2024 Category: Infectious Diseases Authors: Shogo Miyazawa, Ting Sam Wong, Genta Ito, Ryo Iwamoto, Kozo Watanabe, Michiel van Boven, Jacco Wallinga and Fuminari Miura Source Type: research
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity. (Source: Eurosurveillance)
Source: Eurosurveillance - February 22, 2024 Category: Infectious Diseases Authors: Hannah Chung, Michael A Campitelli, Sarah A Buchan, Aaron Campigotto, Natasha S Crowcroft, Jonathan B Gubbay, James KH Jung, Timothy Karnauchow, Kevin Katz, Allison J McGeer, J Dayre McNally, David C Richardson, Susan E Richardson, Laura C Rosella, Margar Source Type: research
Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany ’s experience during the COVID-19 pandemic, July 2021 to March 2023
The screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were produced in real-time for different age groups and clinical outcomes. Here we describe the ...
Source: Eurosurveillance - February 22, 2024 Category: Infectious Diseases Authors: Nita Perumal, Viktoria Sch önfeld and Ole Wichmann Source Type: research
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85). (Source: Eurosurveillance)
Source: Eurosurveillance - February 15, 2024 Category: Infectious Diseases Authors: Danuta M Skowronski, Yuping Zhan, Samantha E Kaweski, Suzana Sabaiduc, Ayisha Khalid, Romy Olsha, Sara Carazo, James A Dickinson, Richard G Mather, Hugues Charest, Agatha N Jassem, In ès Levade, Maan Hasso, Nathan Zelyas, Ruimin Gao and Nathalie Bastien Source Type: research
Gonorrhoea on the rise in Denmark since 2022: distinct clones drive increase in heterosexual individuals
A surge in gonorrhoea in Denmark has occurred since 2022, a 46% increase from 2021. National surveillance, leveraging mandatory reporting and epidemiological data, highlights three distinct clades linked to heterosexual transmission. Despite the rise, these exhibit high susceptibility, contrasting MSM-associated strains. Geographical hotspots and age-specific patterns further illuminate transmission dynamics. The combination of genomic and epidemiological data provides novel insights into the evolving landscape of gonorrhoea, indicating potential shifts in infection dynamics and transmissibility. (Source: Eurosurveillance)
Source: Eurosurveillance - February 15, 2024 Category: Infectious Diseases Authors: Thomas Roland Pedersen, Maria Wessman, Mikkel Lindegaard, S øren Hallstrøm, Casper Westergaard, Inger Brock, Esad Dzajic, Dennis Back Holmgaard, Christian Salgård Jensen, Ulrik Stenz Justesen, Jette Brommann Kornum, Turid Snekloth Søndergaard, Mariann Source Type: research
Estimation of antimicrobial resistance of Mycoplasma genitalium, Belgium, 2022
ConclusionAlthough limited in sample size, our data suggest no additional benefit of testing MG retrieved from MSM for macrolide resistance in Belgium, when making treatment decisions. The lower occurrence of macrolide resistance in other population groups, combined with emergence of fluoroquinolone RAMs support macrolide-resistance testing in these groups. Continued surveillance of resistance in MG in different population groups will be crucial to confirm our findings and to guide national testing and treatment strategies. (Source: Eurosurveillance)
Source: Eurosurveillance - February 15, 2024 Category: Infectious Diseases Authors: Irith De Baetselier, Hilde Smet, Kaat Kehoe, Imelda Loosen, Marijke Reynders, Iqbal Mansoor, Lorenzo Filippin, Mathieu Cauchie, Ellen Van Even, Nadia Makki, Gilberte Schiettekatte, Wouter Vandewal, Bart Glibert, Veerle Matheeussen, Yolien Van der Beken, R Source Type: research
Epidemiology of reported cases of leptospirosis in the EU/EEA, 2010 to 2021
ConclusionThe notification rate of leptospirosis at EU/EEA level increased during 2010−2021 despite including the first 2 years of the COVID-19 pandemic and associated changes in population behaviours. Studies at (sub)national level would help broaden the understanding of differences at country-level and specificities in terms of exposure toLeptospira, as well as biases in diagnosis and reporting. (Source: Eurosurveillance)
Source: Eurosurveillance - February 15, 2024 Category: Infectious Diseases Authors: Julien Beaut é, Francesco Innocenti, Aristos Aristodimou, Michaela Špačková, Caroline Eves, Natalia Kerbo, Ruska Rimhanen-Finne, Mathieu Picardeau, Mirko Faber, Georgios Dougas, Anna Margrét Halldórsdóttir, Sarah Jackson, Viktorija Leitēna, Anne V Source Type: research
Bias in vaccine effectiveness studies of clinically severe outcomes that are measured with low specificity: the example of COVID-19-related hospitalisation
Many vaccine effectiveness (VE) analyses of severe disease outcomes such as hospitalisation and death include‘false’ cases that are not actually caused by the infection or disease under study. While the inclusion of such false cases inflate outcome rates in both vaccinated and unvaccinated populations, it is less obvious how they affect estimates of VE. Illustrating the main points through simple examples, this article shows how VE is underestimated when false cases are included as outcomes. Depending how the outcome indicator is defined, estimates of VE against severe disease outcomes, whose definition allows ...
Source: Eurosurveillance - February 15, 2024 Category: Infectious Diseases Authors: Christian Holm Hansen Source Type: research
Letter to the editor: Further identification of a measles variant displaying mutations impacting molecular diagnostics, Northern Italy, 2024
(Source: Eurosurveillance)
Source: Eurosurveillance - February 15, 2024 Category: Infectious Diseases Authors: Clara Fappani, Maria Gori, Silvia Bianchi, Marta Canuti, Daniela Colzani, Melissa Baggieri, Silvia Gioacchini, Emilio D ’Ugo, Elisabetta Tanzi, Fabio Magurano and Antonella Amendola Source Type: research
